|
HYOU1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.88657986402541E-15 |
| Normal-vs-Stage2 |
6.44260000000063E-05 |
| Normal-vs-Stage3 |
1.88737914186277E-15 |
| Normal-vs-Stage4 |
1.77624581709779E-12 |
| Stage1-vs-Stage2 |
4.618100E-02 |
| Stage1-vs-Stage3 |
9.018500E-04 |
| Stage1-vs-Stage4 |
1.629900E-02 |
| Stage2-vs-Stage3 |
7.988800E-04 |
| Stage2-vs-Stage4 |
1.356360E-03 |
| Stage3-vs-Stage4 |
7.494200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.6805445923751E-12 |
| Normal-vs-AfricanAmerican |
2.22349999999816E-05 |
| Normal-vs-Asian |
1.95254923340826E-12 |
| Caucasian-vs-AfricanAmerican |
3.219000E-01 |
| Caucasian-vs-Asian |
8.223600E-01 |
| AfricanAmerican-vs-Asian |
3.016600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.33066907387547E-16 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
4.521200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.63014046705712E-12 |
| Normal-vs-Age(41-60Yrs) |
3.77475828372553E-15 |
| Normal-vs-Age(61-80Yrs) |
1.7160717291631E-12 |
| Normal-vs-Age(81-100Yrs) |
7.386800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.407600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.767400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.395200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.936600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.748400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.747200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.62296867453915E-13 |
| Classical-VS-Follicular |
2.61410000312878E-08 |
| Classical-VS-Other |
5.928800E-01 |
| Classical-VS-Normal |
2.1316282072803E-14 |
| Tall-VS-Follicular |
1.62481139653892E-12 |
| Tall-VS-Other |
8.158300E-02 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
7.997900E-04 |
| Follicular-VS-Normal |
6.256300E-03 |
| Other-VS-Normal |
1.004170E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.46610518064949E-11 |
| Normal-vs-N1 |
2.22044604925031E-16 |
| N0-vs-N1 |
9.59179999981963E-07 |
|
|
